NASDAQ:ABVX Abivax (ABVX) Stock Price, News & Analysis $142.85 -1.14 (-0.79%) As of 02:41 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Abivax Stock (NASDAQ:ABVX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abivax alerts:Sign Up Key Stats Today's Range$140.56▼$145.0150-Day Range$72.50▼$144.6552-Week Range$7.70▼$148.83Volume844,662 shsAverage Volume1.60 million shsMarket Capitalization$11.40 billionP/E RatioN/ADividend YieldN/APrice Target$146.00Consensus RatingModerate Buy Company Overview Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders. This small molecule has completed Phase 2 studies in rheumatoid arthritis and ulcerative colitis, demonstrating promising efficacy signals and a favorable tolerability profile. In addition, Abivax is exploring obefazimod’s antiviral potential in early-stage programs targeting chronic viral infections, including HIV and hepatitis B. With operations in Europe and strategic development activities in the United States, Abivax collaborates with academic institutions and research centers to advance its pipeline. The company is led by a management team with deep expertise in biotechnology development and regulatory affairs. Under the leadership of CEO Pascal Mélin, Abivax pursues its mission to bring innovative, host-targeted therapies to patients worldwide. AI Generated. May Contain Errors. Read More Abivax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreABVX MarketRank™: Abivax scored higher than 28% of companies evaluated by MarketBeat, and ranked 708th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingAbivax has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Abivax is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAbivax has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Abivax's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Abivax are expected to decrease in the coming year, from ($3.40) to ($3.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abivax is -27.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abivax is -27.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbivax has a P/B Ratio of 22.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abivax's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.13% of the float of Abivax has been sold short.Short Interest Ratio / Days to CoverAbivax has a short interest ratio ("days to cover") of 1.19, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abivax has recently increased by 60.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbivax does not currently pay a dividend.Dividend GrowthAbivax does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.48 News SentimentAbivax has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Abivax this week, compared to 6 articles on an average week.Search InterestOnly 18 people have searched for ABVX on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows5 people have added Abivax to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Abivax insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of Abivax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abivax's insider trading history. Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abivax and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABVX Stock News HeadlinesAbivax: Wall Street Catches Up to the DataAbivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional demand.2 hours ago | marketbeat.comAbivax Announces Closing of $920 Million Public OfferingJuly 6 at 4:05 PM | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 7 at 1:00 AM | Banyan Hill Publishing (Ad)Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX)July 5 at 8:01 AM | theglobeandmail.comABVX stock eyes over six-month high as investors double down on Abivax's lead drug bet – buyout chatter buildsJuly 3, 2026 | msn.comIs ABIVAX Société Anonyme (ABVX) A Good Stock To Buy Now?July 3, 2026 | insidermonkey.comAbivax SA Raises $760 Million in Major U.S. ADS OfferingJuly 2, 2026 | tipranks.comAbivax raises $920M as underwriters fully exercise overallotment optionJuly 2, 2026 | msn.comSee More Headlines ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? Abivax's stock was trading at $134.85 at the beginning of 2026. Since then, ABVX stock has increased by 7.3% and is now trading at $144.6310. How were Abivax's earnings last quarter? Abivax SA Sponsored ADR (NASDAQ:ABVX) announced its quarterly earnings data on Friday, May, 22nd. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. When did Abivax IPO? Abivax (ABVX) raised $230 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60-$13.00 per share. Who are Abivax's major shareholders? Top institutional investors of Abivax include Versant Capital Management Inc. How do I buy shares of Abivax? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abivax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abivax investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), Howard Hughes (HHH) and KT (KT). Company Calendar Last Earnings5/22/2026Today7/07/2026Next Earnings (Estimated)9/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 7 days, ABVX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year Founded2013Price Target and Rating Average Price Target for Abivax$146.00 High Price Target$187.00 Low Price Target$101.00 Potential Upside/Downside+1.0%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($5.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$380.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-99.02% Return on Assets-70.26% Debt Debt-to-Equity RatioN/A Current Ratio8.25 Quick Ratio8.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.57 per share Price / Book22.00Miscellaneous Outstanding Shares79,770,000Free FloatN/AMarket Cap$11.53 billion OptionableNot Optionable Beta0.87 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ABVX) was last updated on 7/7/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
